Company intelligence / Profile preview
Phlox Therapeutics
Naarden, North Holland, Netherlands
- Ownership
- Private
- Employees
- ~7
- Development stage
- Other
01
Overview
Phlox Therapeutics is developing first-in-class RNA-based gene therapies for rare genetic cardiomyopathies, with a lead preclinical program targeting laminopathies (LMNA-related severe inherited heart failure); no clinical trial results have been reported yet, and current funding supports advancement of this lead program through preclinical development.[2][3]
- Therapeutic areas
- CardiovascularRare Diseases
- Modalities
- RNA therapyGene therapy
- Industry
- Biotech
02
Drug pipeline
2 assets1 more asset in the full pipeline.
Request access →03
Partnerships
Solid Biosciences[2]Hubrecht Institute[3]
Beyond the preview
Go deeper on Phlox Therapeutics.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Phlox Therapeutics.